Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

PREGABALINA PENSA 300 MG CAPSULAS DURAS EFG - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/PREGABALINA PENSA 300 MG CAPSULAS DURAS EFG

Approved

STANDARD

PREGABALINA PENSA 300 MG CAPSULAS DURAS EFG

Towa Pharmaceutical S.A.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Nov 3, 2022
Approval ID: 43c37211c4fb2fee
Company: Towa Pharmaceutical S.A.
Type: Standard

Approval Details

Approval Id: 43c37211c4fb2fee
Drug Cima Aemps Name: PREGABALINA PENSA 300 MG CAPSULAS DURAS EFG
Register Number: 88181
Holder Company Name: Towa Pharmaceutical S.A.
Marketing Company Name: Towa Pharmaceutical S.A.
Authorization Date: 2022-11-03
Dosage Form: CÁPSULA DURA
Dose: 300 mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: Yes
Company Name: Towa Pharmaceutical S.A.

Active Ingredients

PREGABALINA

300 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Nov 3, 2022

Approval ID

43c37211c4fb2fee

Type

Standard

Back to CIMA-AEMPS Approvals